{{Rsnum
|rsid=1042389
|Gene=CYP2B6
|Chromosome=19
|position=41018248
|Orientation=plus
|GMAF=0.2355
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP2B6
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 1.8 | 33.6 | 64.6
| HCB | 13.1 | 38.7 | 48.2
| JPT | 9.8 | 33.9 | 56.2
| YRI | 3.5 | 38.7 | 57.7
| ASW | 8.8 | 28.1 | 63.2
| CHB | 13.1 | 38.7 | 48.2
| CHD | 9.3 | 46.3 | 44.4
| GIH | 6.0 | 31.0 | 63.0
| LWK | 12.1 | 40.2 | 47.7
| MEX | 1.8 | 29.8 | 68.4
| MKK | 5.8 | 35.1 | 59.1
| TSI | 2.9 | 25.5 | 71.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1042389
|Name_s=
|Gene_s=CYP2A7P1, CYP2B6
|Feature=
|Evidence=PubMed ID:16538176
|Annotation=Risk or phenotype-associated allele: C allele. Phenotype: Carbamazepine (CBZ)-induced maculopapular exanthema (MPE)/ hypersensitivity syndrome (HSS). Study size: 175. Study population/ethnicity: 31 CBZ-induced MPE/HSS cases and 144 CBZ-tolerant controls of Chinese descent. Significance metric(s): p = 0.001696, OR = 2.51. Type of association: GN; PD; TOX; ADR.
|Drugs=carbamazepine
|Drug Classes=
|Diseases=Drug Hypersensitivity; Exanthema; Maculopapular Exanthema
|Curation Level=Curated
|PharmGKB Accession ID=PA165291960
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1042389
|overall_frequency_n=24
|overall_frequency_d=126
|overall_frequency=0.190476
|n_genomes=17
|n_genomes_annotated=0
|n_haplomes=20
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}